VUNO Med-Chest X-ray

VUNO is a Korean medical AI company founded in Seoul in December 2014 and listed on KOSDAQ in 2021. It builds AI medical devices for imaging, pathology, biosignals and speech to help clinicians read exams faster and catch high-risk patients earlier.

VUNO Med-Chest X-ray analyzes chest radiographs for five major abnormal findings and combines them to support the diagnosis of lung cancer, tuberculosis and pneumonia, marking suspected locations on the image. It was trained on tens of thousands of chest PA X-rays from major Korean hospitals, integrates with PACS, offers APIs and runs as a cloud service. The wider VUNO Med portfolio includes Fundus AI, DeepBrain, LungCT AI and DeepCARS for hospitals and clinics.

• Five-finding detection: flags five major abnormal findings on chest X-rays.
• Disease support: combines findings to support diagnosis of lung cancer, tuberculosis and pneumonia.
• Lesion localization: marks suspected abnormal locations on the radiograph.
• PACS integration: results appear in the existing reading environment, with APIs for configuration.
• Cloud delivery: offered as a cloud-based service with a simple user interface.
• Triage version: VUNO Med-Chest X-ray Triage received FDA 510(k) clearance in November 2024.

District and provincial hospitals in Vietnam could use the software to pre-read chest X-rays for tuberculosis and pneumonia when radiologists are scarce. Health check-up centers could prioritize suspicious lung findings in corporate screening packages. X-ray equipment distributors could bundle the AI with digital X-ray systems sold to clinics.

Helps radiologists and general physicians read common thoracic abnormalities faster and more consistently. Points to suspected lesion locations so urgent cases such as tuberculosis or lung cancer suspects are reviewed first. Plugs into existing PACS and reading systems through integration and APIs. Backed by MFDS breakthrough device status, CE marking and an FDA-cleared triage version.

Chest X-ray is the most common imaging exam in Asia, and tuberculosis and lung cancer screening programs are increasing volumes faster than radiologist supply. Korean medical AI vendors are expanding into Japan, the Middle East and Southeast Asia, and hospitals in Vietnam that already run PACS can add AI reading support as a software layer.

VUNO Inc. was founded in December 2014 and is headquartered at Sinnonhyeon Tower in Seoul, with a US subsidiary, VUNO MED Inc. It has been listed on KOSDAQ since 2021. Its products hold MFDS, CE and FDA clearances, and in 2025 it obtained approvals in Brazil, Indonesia and Saudi Arabia for parts of its portfolio. It holds ISO/IEC 27001 and 27701 certifications.